Business context and reporting period
The supplied filing is IsoRay, Inc.’s Form 10-Q for the quarter ended September 30, 2015, filed November 9, 2015. It does not appear to be a filing for Perspective Therapeutics, Inc.; the company and period in the request metadata should be verified. The quarter is IsoRay’s first quarter of fiscal 2016. IsoRay manufactures and sells Cesium-131 brachytherapy seeds and the GliaSite Radiation Therapy System.
Financial results and liquidity
| Metric | Three months ended September 30, 2015 | Prior-year quarter | Change |
|---|---|---|---|
| Product sales | $1.261 million | $1.042 million | +21% |
| Gross profit (loss) | $83,459 | $(54,802) | Improved by $138,261 |
| Gross margin | 6.6% | (5.3%) | Improved |
| Operating loss | $(1.091) million | $(1.161) million | Loss narrowed 6% |
| Net loss | $(1.019) million | $(786,000) | Loss increased |
| Net loss applicable to common shareholders | $(1.022) million; $(0.02) per share | $(789,000); $(0.01) per share | Loss increased |
| Operating cash flow | $(1.110) million | $(1.143) million | Cash use decreased |
At September 30, 2015, cash and cash equivalents were $1.587 million and certificates of deposit totaled $17.026 million, including $5.135 million classified as non-current. Total cash, cash equivalents and certificates of deposit were $18.613 million. Current assets were $15.340 million versus current liabilities of $931,384; total assets were $21.909 million and total liabilities $2.067 million. The balance sheet reports no interest-bearing debt. Cash and cash equivalents decreased $3.640 million during the quarter, largely reflecting purchases and reinvestment of certificates of deposit. Financing provided $46,735.
Material changes versus the prior-year quarter
- Seed brachytherapy revenue grew approximately 24%, more than offsetting the absence of GliaSite sales; seeds accounted for all product sales versus 98% a year earlier. Prostate brachytherapy represented 88% of revenue in both periods and grew 22%.
- Other brachytherapy revenue, including brain and lung treatments, increased 44%, but management described these newer applications as early-stage and potentially volatile.
- Cost of sales rose 7%, below revenue growth, and gross results turned positive. Management attributed part of the improvement to using previously purchased isotope that otherwise would have been expensed as it decayed.
- Research and development expense decreased 19% and sales and marketing expense decreased 21%. General and administrative expense increased 31%, including higher legal, audit/compliance and occupancy costs.
- Net loss widened despite a narrower operating loss, in part because the prior-year quarter included a larger favorable change in the fair value of the warrant derivative liability.
Outlook, risks and unusual items
Management estimated that available cash and investments as of November 3, 2015 would cover anticipated cash needs for the next three years, assuming revenue and expenses remain at current levels. It cautioned that profitability and revenue growth are not assured and noted that product sales had not reached breakeven-supporting levels over the preceding seven fiscal years or the reported quarter. The company planned to pursue growth in existing and new customers, distributor sales, GliaSite, and additional treatment applications, while controlling costs. Management estimated fiscal 2016 capital equipment spending below $200,000 and approximately $150,000 of protocol-study expense; these are estimates, not guarantees.
- Property purchase: IsoRay’s subsidiary agreed to buy approximately 4.2 acres from the Port of Benton for $168,000, subject to feasibility and development obligations. An October 2015 amendment extended feasibility through January 8, 2016 and closing to on or before February 5, 2016. Development covenants include construction requirements, use as the primary production facility for ten years, and at least 25 full-time jobs; default may require payment based on the property’s appraised value.
- Litigation: An amended securities class-action complaint related to a May 20, 2015 press release names the company and its CEO/Chairman. The company said it would defend the claims; outcome and potential damages were not estimable. The response deadline was December 15, 2015.
- Operating risks: Management cited reimbursement economics for brachytherapy, dependence on adoption by physicians and facilities, lengthy GliaSite approval processes, currency effects on overseas sales, and reliance on certain single-source suppliers subject to regulatory qualification of alternatives. Two customers each represented at least 10% of quarterly revenue; one customer group accounted for 30% of receivables.
- Potential financing: The company said future funding could involve equity, collaboration, debt or other sources, and anticipated that any equity financing could be dilutive.
- Other items: A 1% know-how royalty is disputed by the licensor; management believes no royalty is due and no future use is intended, but binding arbitration may be demanded. Management reported effective disclosure controls and no material change in internal control during the quarter.
Important facts for investors to verify
- Confirm the filing identity: the source is for IsoRay, Inc., not Perspective Therapeutics, Inc., and reports the quarter ended September 30, 2015.
- Check whether seed-revenue growth and improved gross margin persist, particularly given the benefit from consuming previously purchased isotope.
- Monitor cash burn, investment maturities, the assumptions behind management’s three-year liquidity estimate, and any need for potentially dilutive financing.
- Track the Port of Benton property closing, development obligations and any subsequent facility construction commitments.
- Review subsequent developments in the securities lawsuit, the disputed royalty matter, customer concentration, GliaSite adoption and supplier availability.